Lantheus Holdings, Inc.
Could not find a ticker for this position, may be a filing error
A maker of radiopharmaceuticals used to image disease, Lantheus' products include PYLARIFY, an F-18 PET agent that lights up prostate cancer on scans, and DEFINITY, a contrast agent for heart ultrasound. The business began in 1956 as New England Nuclear, founded in Boston, and adopted the coined name "Lantheus" in 2008 when it became an independent company — a made-up brand invented to mark its fresh start.
2.625% Convertible Senior Notes due 2027
Granted 46.4K
Granted 46.5K
Granted 41.9K
Granted 4.1K
Granted 29.0K
Granted 4.1K
Granted 21.0K
Granted 4.1K
Granted 4.1K
Granted 4.1K
Granted 4.1K
Granted 4.1K
Granted 6.2K
Granted 4.1K
Granted 4.1K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Heino Mary AnneExecutive Chair and CEO, Director · 4 transactions | +3% | 625.7K | 46.4K | — | — |
| Marshall Robert J. Jr.CFO and Treasurer · 5 transactions | -4.5% | 122.8K | 46.5K | — | — |
| Niedzwiecki DanielSee Remarks · 5 transactions | +34.9% | 117.5K | 41.9K | — | — |
| Leno Sam RDirector · 1 transaction | +6.6% | 67.2K | 4.1K | — | — |
| Morgan Amanda MichelleChief Commercial Officer · 5 transactions | +63.6% | 64.7K | 29.0K | — | — |
| Thrall James HDirector · 1 transaction | +11.6% | 39.9K | 4.1K | — | — |
| Dinkelborg LudgerSee Remarks · 1 transaction | — | 35.7K | 21.0K | — | — |
| McHugh JulieDirector · 1 transaction | +15.9% | 30.1K | 4.1K | — | — |
| Maeusli Heinz ChristophDirector · 1 transaction | +16% | 30.0K | 4.1K | — | — |
| Pruden Gary JDirector · 1 transaction | +29.5% | 29.7K | 4.1K | — | — |
| Ber GerardDirector · 2 transactions | +17.7% | 27.5K | 4.1K | — | — |
| Baylor-Henry MinnieDirector · 1 transaction | +41.8% | 14.0K | 4.1K | — | — |
| Brown KimberlyChief Accounting Officer · 2 transactions | +80% | 13.9K | 6.2K | — | — |
| Eastland Julia MarieDirector · 1 transaction | +106.6% | 8.0K | 4.1K | — | — |
| Morrow Phuong KhanhDirector · 1 transaction | +133.5% | 7.2K | 4.1K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.